Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: A case report

Cancer Biology and Therapy

Volumn 15, Issue 7, 2014, Pages 826-831

  Capalbo, Carlo ^a,b   Marchetti, Paolo ^b,c   Coppa, Anna ^c   Calogero, Antonella ^a   Anastasi, Emanuela ^a   Buffone, Amelia ^a   Belardinilli, Francesca ^a   Gulino, Matteo ^c   Frati, Paola ^c,d   Catalano, Carlo ^e   Cortesi, Enrico ^e   Giannini, Giuseppe ^a   Gulino, Alberto ^c,d,f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d IRCCS NEUROMED   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

BRAF; Colorectal cancer; Cutaneous toxicity; EGFR; Panitumumab; Personalized medicine; Target therapy; Vemurafenib

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CHLOROPLAST DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; SORAFENIB; VEMURAFENIB; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; SULFONAMIDE;

ADULT; AMPLICON; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURGERY; CARCINOMATOUS PERITONITIS; CASE REPORT; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE FREE INTERVAL; DRUG TOLERABILITY; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; IMMUNOHISTOCHEMISTRY; KERATOACANTHOMA; LIVER BIOPSY; LUNG EMBOLISM; LYMPH NODE DISSECTION; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OFF LABEL DRUG USE; PERSONALIZED MEDICINE; PROTEIN BLOOD LEVEL; SQUAMOUS CELL CARCINOMA; WILD TYPE; ADENOCARCINOMA; COLORECTAL NEOPLASMS; GENETICS; MUTATION; PATHOLOGY; SECONDARY;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; INDOLES; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84903828105     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28878     Document Type: Article

References (31)

1. Moorcraft SY, Smyth EC, Cunningham D. The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therap Adv Gastroenterol 2013; 6:381-95; PMID:24003339; http://dx.doi.org/10.1177/1756283X13491797
2. Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, Karapetis CS, Pavlakis N, Sobrero AF, Cunningham D, et al. Current opinion on optimal treatment for colorectal cancer. Expert Rev Anticancer Ther 2013; 13:597-611; PMID:23617351; http://dx.doi.org/10.1586/era.13.37
3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45; PMID:15269313; http://dx.doi.org/10.1056/NEJMoa033025 (Pubitemid 38944402)
4. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369:1023-34; PMID:24024839; http://dx.doi.org/10.1056/NEJMoa1305275
5. Blanke CD, Goldberg RM, Grothey A, Mooney M, Roach N, Saltz LB, Welch JJ, Wood WA, Meropol NJ; NCI GI Steering Committee Colon Cancer Task Force. KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist 2011; 16:1061-8; PMID:21737577; http://dx.doi.org/10.1634/theoncologist.2011-0011
6. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28:1254-61; PMID:20100961; http://dx.doi.org/10.1200/JCO.2009.24.6116
7. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27:5931-7; PMID:19884549; http://dx.doi.org/10.1200/JCO.2009.22.4295
8. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, Nolop KB, Saltz LD. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol [Internet] 2010; suppl 3534. Available from: http://meetinglibrary. asco.org/content/50595-74
9. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782
10. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2:227-35; PMID:22448344; http://dx.doi.org/10.1158/2159-8290.CD-11-0341
11. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483:100-3; PMID:22281684; http://dx.doi.org/10.1038/nature10868
12. Lewis JR, Lipworth WL, Kerridge IH, Day RO. The economic evaluation of personalised oncology medicines: ethical challenges. Med J Aust 2013; 199:471-3; PMID:24099207; http://dx.doi.org/10.5694/mja13.10046
13. Nardini C. Review: the ethics of clinical trials. ecancer 2014; 8:387-96.
14. Huang T, Karsy M, Zhuge J, Zhong M, Liu D. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol 2013; 6:30; PMID:23617957; http://dx.doi.org/10.1186/1756-8722-6-30
15. Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013; 19:1389-400; PMID:24202392; http://dx.doi.org/10.1038/nm.3388
16. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707-14; PMID:22356324; http://dx.doi.org/10.1056/NEJMoa1112302
17. Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med 2013; 19:1401-9; PMID:24202393; http://dx.doi.org/10.1038/ nm.3392
18. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011; 19:11-5; PMID:21251612; http://dx.doi.org/10.1016/j.ccr.2011. 01.008
19. Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012; 22:668-82; PMID:23153539; http://dx.doi.org/10.1016/j.ccr.2012.10.009
20. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973-7; PMID:21107323; http://dx.doi.org/10.1038/nature09626
21. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464:427-30; PMID:20179705; http://dx.doi.org/10.1038/nature08902
22. Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 2012; 72:969-78; PMID:22205714; http://dx.doi.org/10.1158/0008-5472.CAN-11-1875
23. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18:683-95; PMID:21156289; http://dx.doi.org/10.1016/j.ccr.2010.11.023
24. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012; 72:779-89; PMID:22180495; http://dx.doi.org/10.1158/0008-5472.CAN-11-2941
25. Al-Marrawi MY, Saroya BS, Brennan MC, Yang Z, Dykes TM, El-Deiry WS. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAFmutant metastatic colon cancer. Cancer Biol Ther 2013; 14:703-10; PMID:23792568; http://dx.doi.org/10.4161/cbt. 25191
26. Belum VR, Fischer A, Choi JN, Lacouture ME. Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep 2013; 15:249-59; PMID:23463215; http://dx.doi.org/10.1007/s11912-013-0308-6
27. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-19; PMID:20818844; http://dx.doi.org/10.1056/NEJMoa1002011
28. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr., Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013; 19:657-67; PMID:23251002; http://dx.doi.org/10. 1158/1078-0432.CCR-11-1446
29. Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng Y, Jin W, Black S, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013; 3:742-50; PMID:23614898; http://dx.doi.org/10.1158/2159-8290.CD-13-0070
30. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494:251-5; PMID:23302800; http://dx.doi.org/10.1038/nature11814
31. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19:619-25; PMID:23584089; http://dx.doi.org/10.1038/nm.3175